** Biotech group Oxford Nanopore Technologies ONT.L up as much as 5.7% at 115.9p
** Gene sequencing specialist is now "exposed" to acquisition, CEO and co-founder Gordon Sanghera told FT
** ONT's shares have lost 85% since its peak in 2021
** "Bankers have said it could be attractive to one of the big diagnostics specialists, such as Thermo Fisher Scientific TMO.N or Danaher DHR.N," FT report adds
** As of last close, stock down ~15% this year
(Reporting by Radhika Anilkumar in Bengaluru)
((Radhika.Anilkumar@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。